Shanghai Pharma buys Citic Medicine layout North China market

January 12 Afternoon news, Shanghai Medicine has just announced the acquisition of Citic Medicine and the unveiling of Love Albert, and set up Beijing headquarters.　　Citic Medicine and Beijing pharmaceutical love Albert after further integration, will become the new medicine to north China, Hebei and other land development platform, Shanghai Pharmaceutical is speeding up the process of national progress. At the end of last year, Shanghai Medicine spent 2.328 billion yuan to acquire a controlled stake in China Health System Ltd. 65.24%, thereby acquiring its wholly owned subsidiary, Citic Medicine, which is reported to have completed its 100% acquisition plan for Citic Medicine by the end of March;　　Shanghai Medicine also acquired Beijing Love Albert Pharmaceutical Co., Ltd. Shanghai medicine to buy CITIC Medicine, is the new medicine after the reorganization of the largest one of the mergers and acquisitions, but also the largest medical mergers and acquisitions case in mainland China.　　Citic Medicine to the hospital sales-oriented, ranked third in Beijing, plus love Albert, Shanghai Medicine in Beijing pharmaceutical distribution market share, is expected to surpass the Chinese Medicine holdings, leaped second, after the North medicine shares. Citic Medicine and love Albert both combined, 2011 sales revenue is expected to close to 10 billion yuan, two further integration, will become new medicine to north China to expand the platform.　　A massive march to Beijing as the core of the North China market, which is Shanghai medicine after the acquisition of Guangzhou Zhongshan Medical into the Pearl River Delta, another major strategic breakthrough, the medicine to Tianjin, Hebei and other fields to expand the integration of North China distribution resources. Last year, including the completion of the acquisition, has acquired 9 enterprises, including Fujian Pharmaceutical Co., Ltd., Guangzhou Zhongshan Medical and Pharmaceutical Co., Ltd., they are ranked in the top three in the local market.　　In the logistics configuration, Shanghai medicine is also speeding up the layout, the last year set up the Suzhou Pharmaceutical Supply Chain Management Co., Ltd., is now promoting Shanghai Central Logistics, Ningbo, Qingdao and other major logistics center construction. In the past, Shanghai pharmaceutical business activities concentrated in eastern China, is often regarded as a regional leading enterprises.　　In this case, Shanghai Medicine has basically realized the distribution of nationwide pharmaceutical distribution network in east China, South China and north China. It is reported that the national strategy of medicine not only points to medical distribution, but also point to pharmaceutical manufacturing and retail business, but also covers the development of core resources and capabilities.　　According to the development trend of the industry, in the near stage, Shanghai Medicine will be national strategic focus on the pharmaceutical distribution field. According to the introduction, in the National network construction, the medicine will be in East China, north China, south China accounted for nearly 75% of the market share of the three major regions as the focus, preferential mergers and acquisitions around the dominant enterprises, timing to the southwest and other potential areas to expand.　　At the same time, to match the network resources, speed up the construction of Logistics center, realize the national distribution of logistics resources.　　At present, China's pharmaceutical distribution industry is highly fragmented, according to statistics in 2009, China has more than 13,400 pharmaceutical commercial enterprises, three largest distribution enterprises total market share of only 20.7%, far lower than the United States three largest pharmaceutical distribution Shangyo 90.7% market share, industry integration space is huge. At present, a number of policies are supporting the industry to accelerate integration, the Ministry of Commerce will be issued in the pharmaceutical circulation "Twelve-Five" Planning requirements, pharmaceutical wholesale enterprises to accelerate the merger and reorganization, bigger and stronger, and during this period to form 3 sales of hundreds of billions of large pharmaceutical circulation enterprises, significantly improve the concentration of industry.　　Last October, the Ministry of Industry, the Ministry of Health, the State Drug Administration and other three departments issued the "guidance on speeding up the restructuring of the pharmaceutical industry," also encouraged the advantages of enterprises to implement cross-regional, cross-ownership mergers and acquisitions and joint restructuring, to promote the variety, technology, channels and other resources to the dominant It is concluded that the pharmaceutical industry has entered the era of great integration, and the network resources, especially the advantageous distribution enterprises, have become the most important acquisition object. (Huayan from Beijing)